- NEWS -

WHATS NEW

MARCH 4, 2019
Salzman Group is building new GLP/GMP compliat Analytical laboratories
> read more
January 7, 2019
New Director of Quality Assurance appointed at Salzman Group
> read more
December 31, 2018
Salzman Group is closing a great year of growth
> read more
December 5, 2018
Salzman Group expands its team of Directors
> read more
November 29, 2018
Salzman Group grows and leases 2000 sqm space for a new GMP facility
> read more
November 20, 2018
Salzman Group welcomes a new Director
> read more
May 28, 2018
Salzman Group welcomes two new Directors
> read more
April 23, 2018
Salzman Group receives ISO 17025 accreditation
> read more
October 20, 2017
Salzman Group opens an Australian subsidiary
> read more
September 5, 2017
Minister of Economy and Industry, MK Eli Cohen, visits Salzman Capital Ventures

> read more
September 1, 2017
Radikal Therapeutics awarded Phase 2 Small Business Innovation grant by the National Institutes of Health for investigation of a novel therapy of vitiligo

> read more
August 16, 2017
Minister of Construction, MK Yoav Galant, visits Salzman Capital Ventures
> read more
June 15, 2017
Tisbury Pharmaceuticals secures $32M series A financing to develop novel therapeutic for Glaucoma
> read more
April 3, 2017
Radikal Therapeutics awarded Phase 2 Small Business Innovation grant by the National Institutes of Health for investigation of a novel therapy of hemorrhagic shock

> read more
October 3, 2016
Radikal Therapeutics awarded funding by Health and Human Services (HHS) for development of inhaled chlorine antidote R-107
> read more
September 1, 2016
Radikal Therapeutics awarded Phase 2 Small Business Innovation grant by the National Institutes of Health for investigation of a novel therapy of sepsis
> read more
September 1, 2016
Radikal Therapeutics awarded Phase 2 Small Business Innovation grant by the National Institutes of Health for investigation of a novel therapy of rheumatoid arthritis
> read more

   


back to top